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Abstract
Intracerebral hemorrhage is by far the most destructive form of
stroke. The clinical presentation is characterized by a rapidly
deteriorating neurological exam coupled with signs and symptoms
of elevated intracranial pressure. The diagnosis is easily estab-
lished by the use of computed tomography or magnetic resonance
imaging. Ventilatory support, blood pressure control, reversal of
any preexisting coagulopathy, intracranial pressure monitoring,
osmotherapy, fever control, seizure prophylaxis, treatment of
hyerglycemia, and nutritional supplementation are the cornerstones
of supportive care in the intensive care unit. Dexamethasone and
other glucocorticoids should be avoided. Ventricular drainage
should be performed urgently in all stuporous or comatose patients
with intraventricular blood and acute hydrocephalus. Emergent
surgical evacuation or hemicraniectomy should be considered for
patients with large (>3 cm) cerebellar hemorrhages, and in those
with large lobar hemorrhages, significant mass effect, and a
deteriorating neurological exam. Apart from management in a
specialized stroke or neurological intensive care unit, no specific
medical therapies have been shown to consistently improve
outcome after intracerebral hemorrhage.
Introduction
Intracerebral hemorrhage (ICH) is defined as the spon-
taneous extravasation of blood into the brain parenchyma.
Non-traumatic forms of ICH account for 10% to 30% of all
stroke hospital admissions [1], leading to catastrophic
disability, morbidity, and a mortality of 30% to 50% at
30 days [1]. Death at 1 year varies by different location: 51%
for deep, 57% for lobar, 42% for cerebellar and 65% for
brain stem hemorrhages [2]. In a recent population-based
study, the overall incidence of ICH was estimated to be 12 to
15 cases per 100,000 population [3]. The cost of ICH alone
is estimated to be USD $125,000 per person per year, with a
total cost of USD $6 billion per year in the United States
alone [4,5] related to both acute and chronic medical care
costs, as well as the loss of productivity.
Depending on the underlying cause of hemorrhage, ICH may be
classified as primary when it originates from the spontaneous
rupture of small arterioles damaged by chronic hypertension or
cerebral amyloid angiopathy, representing at least 85% of all
cases; or secondary when associated with vascular malforma-
tions, bleeding related to an ischemic stroke, tumors, abnormal
coagulation [6,7], trauma [8], or vasculitis. In approximately 40%
of the cases, blood may also extend into the ventricles - intra-
ventricular hemorrhage (IVH) - potentially leading to neurological
death related to acute obstructive hydrocephalus resulting in a
substantial worsening of the prognosis.
Despite ongoing attempts to find effective interventions based
on the physiopathological understanding of this disease,
options are limited, and outcomes remain poor. Evidence-
based medical therapies for ICH are limited to guidelines or
options regarding blood pressure (BP) reduction, intracranial
pressure (ICP) monitoring, osmotherapy with adequate fluid
resuscitation, fever and glycemic control, seizure prophylaxis,
and care in a specialized stroke or neurological intensive care
unit (ICU) [9]. Recently published guidelines for the manage-
ment of spontaneous ICH in adults [2] provide a helpful set of
evidence-based recommendations for the management of this
form of stroke. This review summarizes current therapeutic
options for ICH based on the American Heart Association
Guidelines. A summary of the methods for the classification of
the level of evidence is shown in Table 1 [10].
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Risk factors
Hypertension is the most important and prevalent risk factor for
ICH [11]. In a study of 331 patients, hypertension increased
the risk of ICH by more than two-fold, especially in patients
younger than 55 years of age who stopped anti-hypertensive
treatment [12]. Hypertension causes a chronic small-vessel
vasculopathy characterized by fragmentation, degeneration,
and the eventual rupture of small penetrating vessels within the
brain (lipohyalinosis) [13]. Commonly affected structures
include the basal ganglia and thalamus (50%), lobar regions
(33%), and brainstem and cerebellum (17%) [6,14].
Low cholesterol levels have been implicated as a risk factor
for primary ICH. There is controversy regarding this asso-
ciation as the results from case-control and cohort studies
have suggested that lower cholesterol levels imparted an
increased risk of ICH [15-17]. The results of additional
cohort-studies [18] and recent cardiac trials that have
evaluated the effects of statin therapy have failed to confirm
this association [19]. However, the more recent results of the
Stroke Prevention by Aggressive Reduction in Cholesterol
Levels Study (SPARCL) showed that in patients with recent
stroke or transient ischemic attack, 80 mg of atorvastatin per
day reduced the overall incidence of strokes and of
cardiovascular events for over 5 years, despite a small
increase in the incidence of hemorrhagic stroke [20].
Heavy alcohol intake has been implicated as a risk factor for
ICH in recent case-control studies [21-25]. This effect may
be mediated in part by hypertension, but those studies that
controlled for it have supported an independent association.
In theory, alcohol may affect platelet function, coagulation
physiology, and enhance vascular fragility [23].
Cigarette smoking has not been linked to an increased risk of
ICH. However, a retrospective study found that smokers with
hypertension have an increased risk of ICH [12], an effect
that is mediated by hypertension and not by tobacco abuse
per se. Similarly, ICH may be a complication of incidental or
chronic cocaine use [26-28].
Non-modifiable risk factors for ICH include advanced age
[29,30], male gender, and African-American or Japanese
race/ethnicity [28,31]. Cerebral amyloid angiopathy is an
important risk factor for ICH in the elderly. It is characterized
by the deposition of β-amyloid protein in small- to medium-
sized blood vessels of the brain and leptomeninges, which
may undergo fibrinoid necrosis. It can occur as a sporadic
disorder, in association with Alzheimer’s disease, or with
certain familial syndromes (apolipoprotein ε2 and ε4 allele) [7].
Initial approach
Diagnosis
Widespread use of non-enhancing computed tomography
(CT) scan of the brain has dramatically changed the diag-
nostic approach of this disease, making it the method of
choice to evaluate the presence of ICH (Figure 1). CT scan
evaluates the size and location of the hematoma, extension
into the ventricular system, degree of surrounding edema,
and anatomical disruption (Class I, Level of Evidence A).
Hematoma volume may be easily calculated from CT scan
images by use of the ABC÷2 method, a derived formula from
the calculation of the volume of the sphere [32,33].
CT-angiography is not routinely performed in most centers,
but may prove helpful in predicting hematoma expansion and
outcomes [34,35]. In a recent prospective study of 39
patients with spontaneous ICH, focal enhancing foci (contrast
extravasation, ‘spot sign’) seen in initial CT-angiography were
associated with the presence and extent of hematoma
progression with good sensitivity (91%) and negative
predictive value (96%) (Figure 2) [36]. Magnetic resonance
imaging (MRI) techniques, such as gradient-echo (GRE, T2*),
are highly sensitive for the diagnosis of ICH as well. Sensi-
Table 1
Definition of classes and levels of evidence used in AHA recommendations
Class I Conditions for which there is evidence for and/or general agreement that the procedure or treatment is useful and 
effective
Class II Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a 
procedure or treatment
Class IIa Weight of evidence or opinion is in favor of the procedure or treatment
Class IIb Usefulness/efficacy is less well established by evidence or opinion
Class III Conditions for which there is evidence and/or general agreement that the procedure or treatment is not 
useful/effective and in some cases may be harmful
Level of Evidence A Data derived from multiple randomized trials
Level of Evidence B Data derived from a single randomized trial or non-randomized trials
Level of Evidence C Expert Opinion or case studies
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tivity of MRI for ICH is 100%. In the HEME Study, MRI and
CT were equivalent for the detection of acute ICH but MRI
was significantly more accurate than CT for the detection of
chronic ICH [37].
Conventional diagnostic cerebral angiography should be
reserved for patients in whom secondary causes of ICH are
suspected, such as aneurysms, arteriovenous malformations,
cortical vein or dural sinus thrombosis, or vasculitis. Findings
on CT scan or MRI that should prompt angiographic study
include the presence of subarachnoid hemorrhage, IVH,
underlying calcification, or lobar hemorrhage in non-
hypertensive younger patients. The role of angiography after
ICH has been addressed by two studies. Zhu and colleagues
[38] reported abnormalities on angiography in 48% of
patients who were normotensive and younger than 45 years
of age, 49% of patients with lobar hemorrhages, 65% with
isolated IVH, and no abnormalities in patients older than
45 years who had a history of hypertension with subcortical
ICH. In a second study, Halpin and colleagues [39] reported
finding an underlying lesion in 84% of patients that appeared
to have a structural abnormality seen previously on brain
imaging. Diagnostic catheter angiography should be strongly
considered in all patients with primary IVH and younger non-
hypertensive patients with lobar ICH.
Airway control, breathing, and circulation
Rapid neurological deterioration and ensuing loss of
consciousness with impairment of reflexes that maintain the
airway mandate permanent airway control (Figure 3) [40]
(Class I, Level of Evidence B). Failure to recognize imminent
airway loss may result in complications, such as aspiration,
hypoxemia, and hypercapnia. Preferred induction agents for
rapid sequence intubation (RSI) in the setting of ICH include
propofol [41] and etomidate [42] (Table 2), both of which are
short-acting agents that will not obscure the neurological
exam for a prolonged period of time (Class IIA, Level of
Evidence B). Adverse effects of propofol include drug-
induced hypotension that usually responds to fluid infusion
[42]. Adverse effects of etomidate include nausea, vomiting,
myoclonic movements, lowering of seizure threshold [42],
and adrenal suppression [43]. Unfavorable effects on the ICP
have been reported with the use of midazolam [41,44]. In
certain circumstances, neuromuscular paralysis may be
needed as part of RSI. Succinylcholine is the most commonly
administered muscle relaxant for RSI, owing to its rapidity of
onset (30 to 60 s) and short duration (5 to 15 minutes) [45].
However, side effects of succinylcholine include hyperkalemia,
cardiac arrhythmias, exacerbation of neuropathy or myopathy,
malignant hyperthermia, and elevation of intracranial pressure
in patients with intracranial mass lesions [42,46]. For this
reason, in neurological patients, non-depolarizing neuro-
muscular blocking agents, such as cisatracurium [47],
rocuronium [42], or vecuronium, are preferred [48] (Class IIA,
Level of Evidence B). In patients with increased ICP, pre-
medication with intravenous lidocaine for RSI is of
questionable use [49].
Isotonic fluid resuscitation and vasopressors are indicated for
patients in shock [2]. Dextrose-containing solutions should be
avoided as hyperglycemia may be detrimental to the injured
brain [50] (Class III, Level of Evidence C). Additionally, a
thorough laboratory panel should be obtained, including
hematological, biochemical, coagulation profiles, echocradio-
gram and chest X-rays.
Blood pressure control
Extreme levels of BP after ICH should be aggressively but
carefully treated to reduce the risk of hematoma expansion
and to keep and maintain cerebral perfusion pressure (CPP;
CPP = mean arterial pressure (MAP) - ICP). Controversy
exists about the initial treatment of high BP in patients with
ICH. An expanding hematoma may result from persistent
bleeding and/or re-bleeding from a single arteriolar rupture.
Some studies have reported evidence of hematoma growth
from bleeding into an ischemic penumbra zone surrounding
the hematoma [51,52] but other reports have not confirmed
the existence of ischemia at the hypoperfused area in the
periphery of the hematoma.
In the study by Brott and colleagues [53], no association was
demonstrated between hematoma growth and levels of BP,
but the use of anti-hypertensive agents may have negatively
confounded this association. Similarly, initial BP was not
associated with hematoma growth in the Recombinant
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Figure 1
Computed tomography scan of patient with intracerebral hemorrhage.Activated Factor VII ICH Trial [54]. Moreover, aggressive
blood pressure reduction after ICH may predispose to an
abrupt drop in CPP and ischemia, which, in turn, may be
accompanied by elevations of ICP and further neurological
damage. In a recent pilot trial of BP reduction after ICH, 14
patients with supratentorial ICH were randomized to receive
either labetalol or nicardipine within 22 hours of onset to
lower the MAP by 15%. Cerebral blood flow (CBF) studies
were performed before and after treatment with positron
emission tomography and [15O] water. No changes in global
or peri-hematoma CBF were observed [55]. Two additional
studies have demonstrated that a controlled, pharmaco-
logically based reduction in BP has no adverse effects on
CBF in humans or animals [56,57]. BP level has been
correlated with increases in the ICP and volume of the
hematoma but it has been very difficult to explain if hyper-
tension is the cause of hematoma growth or if this is just a
response to elevated ICP in the setting of large volume ICH
to maintain cerebral perfusion.
In general, the American Heart Association Guidelines
indicate that systolic blood pressures exceeding 180 mmHg
or MAP exceeding 130 mmHg should be managed with
continuous infusion antihypertensive agents such as labetalol,
esmolol, or nicardipine [2] (Class IIB, Level of Evidence C).
Urapidil, a sympatholytic agent with vasodilator properties is
an alternative but it is currently not approved for use in the
US. Use of nitroprusside has drawbacks since this agent may
exacerbate cerebral edema and intracranial pressure [58].
Oral and sub-lingual agents are not preferred, because of the
need for immediate and precise BP control. There are few, if
any, comparative or randomized trials providing definitive
conclusions about the efficacy and safety of comparative
agents.
In comatose patients, it is recommended to monitor ICP and
to titrate vasopressors to maintain CPP in the range 70 to
90 mmHg. Use of brain tissue oxygen and thermodilution CBF
probes to detect reductions in perfusion related to excessive
lowering of BP is gaining in popularity. In general, no matter
how high the BP is, the MAP should not be reduced beyond
15% to 30% over the first 24 hours [56]. In the setting of
impaired blood flow autoregulation, excessive blood pressure
reduction may exacerbate ischemia in the area surrounding
the hematoma and worsen perihematomal brain injury [59,60]
(Table 2; Figure 3). In fact transcranial doppler velocities
become positively correlated with CPP when CPP drops
below the left side of the autoregulation curve [61].
Whether more aggressive BP reduction after ICH is safe is
the matter of the ongoing National Institute of Neurological
Diseases and Stroke supported Antihypertensive Treatment
in Acute Cerebral Hemorrhage (ATACH) pilot study [62].
Additionally, the ongoing phase III Intensive Blood Pressure
Reduction in Acute Cerebral Hemorrhage Trial (INTERACT)
will test the hypothesis that lowering BP acutely after ICH will
reduce the chances of dying or surviving with long-term
disability [63].
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Figure 2
Contrast extravasation seen in the hematoma of a patient with acute coagulopathic intracerebral hemorrhage (white arrows).Though no prospective study has addressed the timing of
conversion from intravenous to oral anti-hypertensive manage-
ment, this process can generally be started after 24 to
72 hours, as long as the patient’s condition has stabilized [6].
Initial emergency intracranial pressure management
Emergency measures for ICP control are appropriate for
stuporous or comatose patients, or those who present acutely
with clinical signs of brain stem herniation (that is, pupillary
abnormalities or motor posturing; Figure 3). The head should
be elevated to 30 degrees, 1.0 to 1.5 g/kg of 20% mannitol
should be administered by a rapid infusion, and the patient
should be hyperventilated to a pCO2 of 26 to 30 mmHg (Class
IIA, Level of Evidence B). As a second line therapy, or if the
patient is relatively hypotensive, 0.5 to 2.0 ml/kg of 23.4%
saline solution can be administered through a central venous
line [64] (Class IIA, Level of Evidence B). These measures are
designed to lower ICP as quickly and effectively as possible, in
order to ‘buy time’ before a definitive neurosurgical procedure
(craniotomy, ventriculostomy (Class IIA, Level of Evidence B), or
placement of an ICP monitor) can be performed (Table 3).
Corticosteroids are contraindicated based on the results of
randomized trials that have failed to demonstrate their efficacy in
ICH [65,66] (Class III, Level of Evidence B). Neurosurgical
consultation is warranted for those patients with rapidly declin-
ing mental status and hydrocephalus with IVH seen in the initial
CT scan. Early placement of a ventricular drain in this case may
be life-saving [67] (Class IIA, Level of Evidence B; Figure 3).
Hemostatic therapy
Hematoma size is an important determinant of mortality after
ICH and early hematoma growth, which is the increase in
Available online http://ccforum.com/content/12/6/237
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Table 2
Intravenous antihypertensive agents for acute intracerebral hemorrhage
Drug Mechanism Dose Cautions 
Labetalol Alpha-1, beta-1, beta-2 receptor  20-80 mg bolus every 10 minutes,  Bradycardia, congestive heart failure, 
antagonist up to 300 mg; 0.5 to 2.0 mg/minute  bronchospasm, hypotension 
infusion
Esmolol Beta-1 receptor antagonist 0.5 mg/kg bolus;  Bradycardia, congestive heart failure, 
50 to 300 μg/kg/minute bronchospasm
Nicardipine L-type calcium channel blocker  5 to 15 mg/h infusion Severe aortic stenosis, myocardial 
(dihydropyridine) ischemia, hypotension
Enalaprilat ACE inhibitor 0.625 mg bolus; 1.25 to 5 mg  Variable response, precipitous fall in blood 
every 6 h pressure with high-renin states
Fenoldopam Dopamine-1 receptor agonist 0.1 to 0.3 μg/kg/minute Tachycardia, headache, nausea, flushing, 
glaucoma, portal hypertension
Nitroprusside* Nitrovasodilator (arterial and venous) 0.25 to 10 μg/kg/minute Increased intracranial pressure, variable 
response, myocardial ischemia, 
thiocyanate and cyanide toxicity, 
hypotension
*Nitroprusside is not recommended for use in acute intracerebral hemorrhage because of its tendency to increase intracranial pressure. Modified
with permission from Mayer SA, Rincon F: Management of intracerebral hemorrhage. Lancet Neurol 2005, 4:662-672. ACE, angiotensin-
converting enzyme.
Figure 3
Approach to intracerebral hemorrhage from the emergency department
to the intensive care unit.hematoma size within 6 hours after onset, is consistently
associated with poor clinical outcomes [53,68-70] and an
increased mortality rate [70]. As a corollary, hematoma growth
occurs in only 5% of patients who are initially scanned
beyond 6 hours of symptom onset. Similarly, significantly
greater reductions in the Glasgow Coma Scale (GCS) and
National Institute of Health Stroke Scale (NIHSS) have been
reported among patients with documented hematoma growth
on 1-hour follow-up CT scans, versus those without growth
[53]. These observations suggest that the reduction in
hematoma growth may be an important strategy for improve-
ment of survival and outcome after ICH.
To be effective, hematostatic therapy must be given early
after the onset of ICH. Even if a hemostatic intervention is
completely effective, substantial hematoma enlargement (that
is, a >33% increase from baseline) would be expected to
occur in 10%, 17% and 21% of patients after a 15-, 30-, or
45-minute treatment delay following the baseline scan [53].
Underlying this principle is the fact that the only consistently
identified predictor of early hematoma growth is the interval
from the onset of symptoms to CT: the earlier the first scan is
obtained, the more likely subsequent bleeding will be
detected on a follow-up scan [53,69,70]. Importantly, hema-
toma growth occurs in only 5% of patients who are initially
scanned beyond 6 hours of symptom onset[53,69,70].
Recombinant factor VII (rFVIIa, Novoseven®, Novo Nordisk) is
a powerful initiator of hemostasis that is currently approved
for the treatment of bleeding in patients with hemophilia who
are resistant to factor VIII replacement therapy. Considerable
evidence exists suggesting that rFVIIa may enhance hemo-
stasis in patients with normal coagulation systems as well. In
a randomized, double blind, placebo controlled study, 399
patients with spontaneous ICH received treatment with rFVIIa
at doses of 40, 80, or 160 μg/kg within 4 hours after ICH
onset. The primary outcome of the study was change in
hematoma volume at 24 hours, a direct measure of hematoma
growth. Secondary outcomes included clinical outcome at
three months as measured by Modified Ranking Scale,
Barthel Index, Extended GCS and NIHSS. Use of rFVIIa was
associated with a 38% reduction in mortality and significantly
improved functional outcomes at 90 days, despite a 5%
increase in the frequency of arterial thromboembolic adverse
events [71]. A similar pilot trial of epsilon aminocaproic acid,
an anti-fibrinolytic agent, has been conducted with negative
results [72].
In May of 2008, the results of the phase III Factor VIIa for
Acute Hemorrhagic Stroke Trial (FAST) were published. This
study compared doses of 80 and 20 μg/kg of rFVIIa with
placebo in an overall trial population of 841 patients. No
significant difference was found in the main outcome
measure, which was the proportion of patients suffering
death or with severe disability according to the modified
Rankin scale at 90 days (score of 5 or 6) but the hemostatic
effect and side effect profiles were confirmed [73] . On the
basis of these results, routine use of rFVIIa as a hemostatic
therapy for all patients with ICH within a 4-hour time window
cannot be recommended (Class III, Level of Evidence B).
Future studies to test rFVIIa in younger patients who present
within an earlier time-frame are needed.
Reversal of anticoagulation
Anticoagulation with warfarin increases the risk of ICH by 5-
to 10-fold in the general population [74], and approximately
15% of ICH cases overall are associated with its use. Among
ICH patients, warfarin increases the risk of progressive
bleeding and clinical deterioration, and doubles the risk of
mortality [75]. Failure to rapidly normalize the international
normalized ratio (INR) to below 1.4 further increases these
risks [76]. Patients with ICH receiving warfarin should be
reversed immediately with fresh frozen plasma (FFP; Class
IIB, Level of Evidence B) or prothrombin-complex concentrate
[77,78] (Class IIB, Level of Evidence B), and vitamin K (Class
I, Level of Evidence B) [79] (Table 4). Treatment should never
Critical Care    Vol 12 No 6 Rincon and Mayer
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Table 3
Stepwise treatment protocol for elevated intracranial pressure* in a monitored patient in the intensive care unit
1. Surgical decompression Consider repeat CT scanning, and definitive surgical intervention or ventricular drainage
2. Sedation Intravenous sedation to attain a motionless, quiet state
3. CPP optimization Vasopressor infusion if CPP is <70 mmHg, or reduction of blood pressure if CPP is >110 mmHg 
(preferred agents are phenylephrine, vasopressin, nor-epinephrine)
4. Osmotherapy Mannitol 0.25 to 1.5 g/kg IV or 0.5 to 2.0 ml/kg 23.4% hypertonic saline (repeat every 1 to 6 hours as 
needed)
5. Controlled  hyperventilation Target  PaCO2 levels of 26 to 30 mmHg
6. High dose pentobarbital therapy Load with 5 to 20 mg/kg, infuse 1 to 4 mg/kg/h
7. Hypothermia Cool core body temperature to 32 to 33°C
*Elevated intracranial pressure ≥20 mmHg. Adapted from Mayer SA, Chong J: Critical care management of increased intracranial pressure. J Int
Care Med 2002, 17:55-67. CPP, cerebral perfusion pressure; CT, computed tomography; IV, intravenous; PaCO2 = arterial partial pressure of
carbon dioxide.be delayed in order to check coagulation tests. Unfortunately,
normalization of the INR with this approach usually takes
several hours, and clinical results are often poor. The
associated volume load with FFP may also cause congestive
heat failure in the setting of cardiac or renal disease.
Prothrombin complex concentrate contains vitamin K-depen-
dent coagulation factors II, VII, IX, and X, normalizes the INR
more rapidly than FFP, and can be given in smaller volumes,
but carries a higher risk for developing disseminated intra-
vascular coagulation [76].
Recent reports have described the use of rFVIIa to speed the
reversal of warfarin anticoagulation in ICH patients [80]. A
single intravenous dose of rFVIIa can normalize the INR within
minutes, with larger doses producing a longer duration of
effect, a response seen in healthy volunteers [81]. Doses of
rFVIIa ranging from 10 to 90 μg/kg have been used to reverse
the effects of warfarin in acute ICH in order to expedite acute
neurosurgical interventions with good clinical results (Class
IIB, Level of Evidence C) [80,82]. When this approach is
used, rFVIIa should be used as an adjunct to coagulation
factor replacement and vitamin K, since its effect lasts only
several hours. Patients with ICH who have been anti-
coagulated with unfractionated or low-molecular weight
heparin should be reversed with protamine sulfate [83] (Class
I, Level of Evidence B) and patients with thrombocytopenia or
platelet dysfunction can be treated with a single dose of
desmopressin, platelet transfusions, or both [84] (Class IIB,
Level of Evidence C) (Table 4). Re-starting anticoagulation in
patients with a strong indication, such as a mechanical heart
valve or atrial fibrillation with a history of cardioembolic stroke,
can be safely implemented after 10 days [85].
Intensive care unit management
Observation in an ICU or similar setting is strongly recom-
mended for at least the first 24 hours after ictus (Class I,
Level of Evidence B), since the risk of neurological deteri-
oration is highest during this period [86] and because the
majority of patients with brain stem or cerebellar hemorrhage
have depressed levels of consciousness requiring ventilatory
support [40] (Figure 3). Measurements in the ICU indicated
for the optimal cardiovascular monitoring of ICH patients
include invasive arterial blood pressure, central venous
pressure, and, if required, pulmonary artery catheter monitor-
ing. An external ventricular drain should be placed in patients
with a depressed level of consciousness (GCS score ≤8),
signs of acute hydrocephalus or intracranial mass effect on
CT, and a prognosis that warrants aggressive ICU care [87].
Outcomes after ICH are better when patients are cared for in
specialized ICUs. In a large administrative database, Diringer
and colleagues [88] demonstrated that mortality after ICH
was associated with lower GCS scores, higher age, and
admission to a general medical-surgical, as opposed to
specialty neurological, ICU. In this study a clear impact on
outcomes was seen when patients were admitted and cared
for by a specialized neurocritical care team. Similarly, in the
study by Mirski and colleagues [89], mortality and disposition
at discharge in ICH patients treated in a neuro-ICU compared
to a similar cohort treated 2 years earlier in a general ICU
setting. Although the exact reason why improved outcomes
occur with treatment in a dedicated neuro-ICU remains
unclear, much attention has focused recently on the major
role that therapeutic nihilism and self-fulfilling prophesies of
doom can have in determining outcome after ICH [90,91].
Patient positioning
To minimize ICP and reduce the risk of ventilator-associated
pneumonia in mechanically ventilated patients, the head
should be elevated 30 degrees (Class IIA, Level of Evidence
B). In mechanically ventilated patients, further need for head
elevation should be guided by changing of pulmonary and
volume needs.
Fluids
Isotonic fluids such as 0.9% saline at a rate of approximately
1 ml/kg/h should be given as the standard intravenous
replacement fluid for patients with ICH and optimized to
achieve euvolemic balance and an hourly diuresis of
>0.5 cc/kg (Class I, Level of Evidence B). Free water given in
the form of 0.45% saline or 5% dextrose in water can exacer-
bate cerebral edema and increase ICP because it flows down
its osmotic gradient into injured brain tissue (Class III, Level
of Evidence C) [50]. Systemic hypo-osmolality
(<280 mOsm/L) should be aggressively treated with mannitol
or 3% hypertonic saline (Class IIA, Level of Evidence B). A
state of euvolemia should be maintained by monitoring fluid
balance and body weight, and by maintaining a normal central
venous pressure (range 5 to 8 mmHg). Careful interpretation
of the central venous pressure should be done when
analyzing its value in the setting of positive end-expiratory
pressure (PEEP).
The use of hypertonic saline in the form of a 2% or 3%
sodium/chloride-acetate solution (1 ml/kg/h) has become an
increasingly popular alternative to normal saline as a resusci-
tation fluid for patients with significant perihematomal edema
and mass effect after ICH (Class IIA, Level of Evidence B).
The goal is to establish and maintain a baseline state of hyper-
osmolality (300 to 320 mOsms/L) and hypernatremia (150 to
155 mEq/L), which may reduce cellular swelling and the
number of ICP crises. Potential complications of hypertonic
saline use are fluid overload, pulmonary edema, hypokalemia,
cardiac arrhythmias, hyperchloremic metabolic acidosis, and
dilutional coagulopathy, [92]. Hypertonic saline should be
gradually tapered and the serum sodium level should never be
allowed to drop more than 12 mEq/L over 24 hours, to avoid
rebound cerebral edema and increased ICP [92,93].
Prevention of seizures
Acute seizures should be treated with intravenous lorazepam
(0.05 to 0.1 mg/kg) followed by a loading dose of phenytoin
Available online http://ccforum.com/content/12/6/237
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Figure 3). An alternative to phenytoin infusion is levetiracetam
(500 mg q12h, adjusted for renal insufficiency). Side effects
of phenytin infusions include rash, hypotension, arrhythmias,
and severe hypocalcemia for the phosphenytoin presentation.
Patients with ICH may benefit from prophylactic anti-epileptic
drug therapy, but no randomized trial has addressed the
efficacy of this approach. The American Heart Association
Guidelines have recommended anti-epileptic medication for
up to one month, after which therapy should be discontinued
in the absence of seizures [94]. This recommendation is
supported by the results of a recent study that showed that
the risk of early seizures was reduced by prophylactic anti-
epileptic drug therapy [95]. The 30-day risk for convulsive
seizures after ICH is approximately 8%, and the risk of overt
status epilepticus is 1% to 2% [95]. Lobar location and small
hematomas are independent predictors of early seizures [95].
The argument for prophylactic anticonvulsant therapy in
stuporous or comatose ICH patients is bolstered by the fact
that continuous electroencephalogram monitoring demon-
strates electrographic seizure activity in approximately 25%
of these patients, despite prophylactic anti-epileptic drug
therapy [96,97]. The risk of late seizures or epilepsy among
survivors of ICH is 5% to 27% [95].
Temperature control
Fever (temperature >38.3°C) after ICH is common, particu-
larly with IVH [98], and should be treated aggressively
(Figure 3; Class I, Level of Evidence C). Sustained fever after
ICH has been shown to be independently associated with
poor outcome after ICH [99]. A large body of experimental
evidence indicates that even small degrees of hyperthermia
can worsen ischemic brain injury by exacerbating excitotoxic
neurotransmitter release, proteolysis, free radical and cyto-
kine production, blood-brain barrier compromise, and apop-
tosis [100,101]. Brain temperature elevations have also been
associated with hyperemia, exacerbation of cerebral edema,
and elevated intracranial pressure [102,103].
As a general standard, acetaminophen and cooling blankets
are recommended for almost all patients with sustained fever
in excess of 38.3°C (101.0°F), despite the lack of prospec-
tive randomized controlled trials supporting this approach
[104,105]. Acetaminophen should be used with caution in
patients with hepatic dysfunction. Newer adhesive surface
cooling systems and endovascular heat exchange catheters
have been shown to be much more effective for maintaining
normothermia [106,107]; however, it remains to be seen if
these measures can improve clinical outcome.
Management of hyperglycemia
Admission hyperglycemia is a potent predictor of 30-day
mortality in both diabetic and non-diabetic patients with ICH
[108]. The detrimental effect of hyperglycemia has been well
studied in acute vascular syndromes. In ischemic stroke,
hyperglycemia occurs in 20% to 40% of patients and is
associated with infarct expansion, worse functional outcome,
longer hospital stays, higher medical costs, and an increased
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Table 4
Emergency management of the coagulopathic intracerebral hemorrhage patient
Level of 
Scenario Agent Dose Comments Evidence*
Warfarin Fresh frozen plasma 15 ml/kg Usually 4 to 6 units (200 ml) each are given B
or
Prothrombin complex  15 to 30 U/kg Works faster than fresh frozen plasma, but carries  B
concentrate risk of disseminated intravascular coagulation
and
Intravenous vitamin K 10 mg Can take up to 24 hours to normalize international  B
normalized ratio
Warfarin and emergency  Above plus rFVIIa 20 to 80 μg/kg Contraindicated in acute thromboembolic disease C
neurosurgical intervention
Unfractionated or  Protamine sulfate 1 mg per 100 units  Can cause flushing, bradycardia, or hypotension,  C
low molecular weight  of heparin, or  anticoagulation
heparin† 1 mg of enoxaparin
Platelet dysfunction  Platelet transfusion 6 units Range 4 to 8 units based on size;  C
or thrombocytopenia transfuse to >100,000
and/or
Desmopressin (DDAVP) 0.3 μg/kg Single dose required C
*See Table 1 for descriptions of Levels of Evidence. †Protamine has minimal efficacy against danaparoid or fondaparinux. Reproduced with
permission from Mayer SA, Rincon F: Management of intracerebral hemorrhage. Lancet Neurol 2005, 4:662-672. rFVIIa, recombinant factor VII.risk of death [109-111] and it is felt to be secondary to a
catecholamine surge and generalized stress response [110].
In the critically ill population, hyperglycemia seems much
more acutely toxic than in healthy individuals, for whom cells
can protect themselves by down-regulation of glucose
transporters [112]. The acute toxicity of high levels of glucose
in critical illness might be explained by an accelerated cellular
glucose overload and more pronounced toxic side effects of
glycolysis and oxidative phosphorylation [113]. Neurons and
several other cell types are insulin independent for glucose
uptake, which is mediated by transporters such as GLUT-1,
GLUT-2, and GLUT-3 [114]. These transporters are up-regu-
lated by hypoxia and inflammatory mediators such as angio-
tensin-II, endothelin-1, vascular endothelial growth factor, and
transforming growth factor-β among others. These trans-
porters facilitate glucose entry into the neuron where intra-
cellular hyperglycemia can lead to oxidative stress and exag-
gerated production of superoxide species [114]. Peroxy-
nitrite, superoxide, and other reactive oxygen species lead to
inhibition of the glycolytic enzyme glyceraldhyde phosphate
dehydrogenase and mitochondrial complexes I and IV, the
basis of mitochondrial dysfunction likely to induce end-organ
failure and cellular death [114].
Strict glucose control after ICH is recommended (Class IIA,
Level of Evidence C). This approach has been linked to
reductions in intracranial pressure, duration of mechanical
ventilation, and seizures in an heterogeneous cohort of
critically ill patients [115].
Elevated intracranial pressure management
Large volume ICH carries the risk of developing cerebral
edema and high ICP (≥15 mmHg or ≥20 mmH2O), and the
presence of IVH further increases the risk of mortality
[116,117] (Figure 3). This effect is primarily related to the
development of obstructive hydrocephalus and alterations of
normal cerebrospinal fluid flow-dynamics. Patients with large
volume ICH, intracranial mass effect, and coma may benefit
from ICP monitoring, though this intervention has not been
proved to benefit outcomes after ICH [118,119]. We
recommend a stepwise protocol for addressing intracranial
hypertension in the ICU setting.
Cerebrospinal fluid drainage
Initial cerebrospinal fluid drainage may be a life-saving
procedure particularly in the setting of hydrocephalus and
IVH [67] (Class IIA, Level of Evidence B). This technique
allows for rapid clearance of cerebrospinal fluid, release of
ICP, and ICP/CPP monitoring. As a general rule, an ICP
monitor or external ventricular drain (EVD) should be placed
in all comatose ICH patients (GCS score of 8 or less) with
the goal of maintaining ICP less than 20 mmH2O
(<15 mmHg) and CPP at greater than 70 mmHg, unless their
condition is so dismal that aggressive ICU care is not
warranted. Compared to parenchymal monitors, EVDs carry
the therapeutic advantage of allowing cerebrospinal fluid
drainage, and the disadvantage of a substantial risk of
infection (approximately 10% during the first 10 days) [120].
A small retrospective study failed to show any relationship
between changes in ventricular size and level of
consciousness in ICH patients treated with EVDs [121].
Sedation
Sedation should be used to minimize pain, agitation, and
decrease surges in ICP (Class IIA, Level of Evidence B).
Agitation must be avoided, because it can aggravate ICP
elevation through straining (increasing thoracic, jugular
venous, and systemic BP), increased cerebral metabolic rate
of oxygen, and also may cause uncontrolled hyper-/hypo-
ventilation, which both can be detrimental. During an ICP
spike, sedation may be all that is necessary to control the
ICP. The goal of sedation should be a calm, comfortable, and
cooperative state in patients with ICP that is well-controlled,
and a quiet, motionless state in patients where ICP elevation
requires active management. The preferred regimen is the
combination of a short-acting opioid, such as fentanyl (1 to
3 μg/kg/h) or remifentanyl (0.03 to 0.25 μg/kg/minute), to
provide analgesia, and propofol (0.3 to 3 mg/kg/h) because
of its extremely short half-life, which makes it ideal for periodic
interruption for neurological assessments, which should be
performed on a daily basis unless the patient has demon-
strated that the ICP is too unstable (frequent ICP crisis in the
setting of awakening, position changes, fever, and so on) to
tolerate this. Bolus injections of opioids should be used with
caution in patients with elevated ICP because they can
transiently lower MAP and increase ICP due to autoregulatory
vasodilation of cerebral vessels [122]. Compared to an
opiod-based sedation regimen, in one trial propofol was
associated with lower ICP and fewer ICP interventions in
patients with severe traumatic brain injury [123]. However,
propofol has been associated with mithocondrial dysfunction
and multi-organ failure (propofol infusion syndrome). Predis-
posing factors include young age, severe critical illness of
central nervous system or respiratory origin, exogenous cate-
cholamine or glucocorticoid administration, inadequate carbo-
hydrate intake and subclinical mitochondrial disease [124].
Cerebral perfusion pressure optimization
Two prevailing management strategies for the management
of elevated ICP have evolved from the experience in traumatic
brain injury. The ‘Lund concept’ assumes a disruption of the
blood brain barrier and recommends manipulations to
decrease the hydrostatic BP and increase osmotic pressures
to minimize cerebral blood volume and vasogenic edema by
improving perfusion and oxygenation to the injured areas of
the brain [125]. This is achieved in theory by maintaining an
euvolemic state with normal hemoglobin, hematocrit, plasma
protein concentrations, and by antagonizing vasoconstriction
through reduction of catecholamine concentration in plasma
and sympathetic outflow. These therapeutic measures attempt
to normalize all essential hemodynamic parameters (blood
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volumes, arterial partial pressure of oxygen (PaO2), and
arterial partial pressure of carbon dioxide (PaCO2)). The
introduction of microdialysis with novel physiological targets
may optimize the goals of the original Lund protocol. The
‘Rosner concept’ emphasizes maintaining a high CPP to
minimize reflex vasodilatation or ischemia [126,127] at the
expense of added cardiopulmonary stress (Class IIA, Level of
Evidence B). Computerized bedside graphical displays (ICU
Pilot®, CMA Micodialysis, Solna, Sweden) can allow
clinicians to identify whether ICP and MAP are positively
correlated, in which case a low CPP would be preferable, or
negatively correlated, in which case a higher CPP would be
desirable.
Hyperosmolar therapy
Hyperosmolar therapy [128] should be used after sedation
and CPP optimization fail to normalize ICP (Class IIA, Level of
Evidence B). The initial dose of mannitol is 1 to 1.5 g/kg of a
20% solution, followed by bolus doses of 0.25 to 1.0 g/kg as
needed to a target osmolality of 300 to 320 mOsm/kg.
Additional doses can be given as frequently as once an hour,
based on the initial response to therapy with the anticipation
of a transient drop in BP. There is little to recommend the use
of standing mannitol in patients with normal ICP. In a recent
trial of mannitol for ICH, 128 patients were randomized to
receive low-dose mannitol (100 ml of 20% solution) or sham
therapy every 4 hours for 5 days with a rapid dose tapering
schedule over 48 hours. The 1-month mortality rate was 25%
in both groups and disability scores at 3 months were not
significantly different between groups [129]. Hypertonic
saline, such as 23.4% saline solution, can be used as an
alternative to mannitol, particularly when CPP augmentation
is desirable (Class IIA, Level of Evidence B). However, care
should be taken to avoid fluid overload in the setting of heart
or kidney failure. Additional side effects of hyperosmolar
therapy include kidney failure, rebound ICP, electrolytic
imbalance (hypo-/hyper-natremia), and acid/base distur-
bances. Despite clinical and animal model support [64], many
issues remain to be clarified, including the exact mechanism
of action, best mode and timing of administration, and the
most appropriate concentration.
Hyperventilation
Forced hyperventilation is generally used sparingly in the ICU
and, for brief periods, in monitored patients, because its
effect on ICP tends to last for only a few hours (Class IIA,
Level of Evidence B). Good long term outcomes can occur
when the combination of osmotherapy and hyperventilation is
successfully used to reverse transtentorial herniation [130].
Overly aggressive hyperventilation to pCO2 levels <25 mmHg
may cause excessive vasoconstriction and exacerbation of
ischemia during the acute phase of ICH and should be
avoided. Controlled hyperventilation therapy can be optimized
by saturation of jugular vein oxygen and partial brain tissue
oxygenation monitoring.
Barbiturates
For cases of severe and intractable intracranial hypertension,
barbiturates can control ICP by decreasing cerebral
metabolic activity, which translates into a reduction of the
CBF and cerebral blood volume (Class IIB, level of Evidence
B). Pentobarbital can be given in repeated 5 mg/kg boluses
every 15 to 30 minutes until ICP is controlled (usually 10 to
20 mg/kg is required), and then continuously infused at 1 to
4 mg/kg/h. An electroencephalogram should be continuously
recorded, and the pentobarbital titrated to produce a burst-
suppression pattern, with approximately 6 to 8 second
interbursts, to avoid excessive sedation.
Hypothermia
If pentobarbital fails to control ICP, induced hypothermia to
32 to 34°C can effectively lower otherwise refractory ICP
(Class IIB, Level of Evidence C) [131]. Hypothermia can be
achieved using various surface and endovascular cooling
systems coupled to a rectal, esophageal, pulmonary artery, or
bladder thermometer. Complications of hypothermia include
nosocomial infection, hypotension, cardiac arrhythmias,
coagulopathy, shivering, hyperkalemia, hyperglycemia, and
ileus. Because these risks increase with the depth and
duration of cooling, some advocate for the induction of mild
hypothermia (34 to 36°C) if temperature reduction is required
for a prolonged period of time to control ICP [104,132,133].
Intraventricular thrombolytic therapy
IVH commonly results from extension of ICH into the cerebral
ventricular system, and is an independent predictor of
mortality after ICH [134]. Commonly, hydrocephalus and IVH
are managed with an EVD, but outcomes remain poor [9].
Intraventricular administration of the plasminogen activator
urokinase every 12 hours may reduce hematoma size and the
expected mortality rate at 1 month [135]. Several small studies
have reported the successful use of urokinase or tissue
plasminogen activator (t-PA) for the treatment of IVH, with the
goal of accelerating the clearance of IVH and improving
clinical outcome [136]. A Cochrane systematic review
published in 2002 summarized the experience of several case
series providing evidence of safety but no definitive efficacy
[137]. No randomized prospective controlled trial has
addressed the efficacy of intraventricular thrombolysis after
ICH. The ongoing Clear IVH Trial (Clot Lysis Evaluating
Accelerated Resoution of Intra Ventricular Hemorrhage), a
phase II multicenter study evaluating recombinant t-PA
treatment of patients with IVH, is designed to investigate the
optimum dose and frequency of recombinant t-PA
administered via an intraventricular catheter to safely and
effectively treat IVH and will soon provide some insight into
this issue [138]. When used off-label, a dose of 1 mg of t-PA
every 8 hours (followed by clamping of the EVD for 1 hour) is
reasonable until clearance of blood from the third ventricle has
been achieved [139]. Doses of 3 mg or more of t-PA for IVH
thrombolysis have been associated with an unacceptably high
bleeding rate (Daniel Hanley, MD, personal communication).
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Patients with ICH are at high risk for deep vein thrombosis
and pulmonary embolism, a potentially fatal complication, due
to limb paresis and prolonged immobilization. Dynamic
compression stockings should be placed on admission [140]
(Class I, Level of Evidence B). A small prospective trial has
shown that low dose subcutaneous heparin (5000 U BID)
starting after the second day significantly reduces the
frequency of venous thromboembolism, with no increase in
intracranial bleeding (Class IIB, Level of Evidence B) [141].
Treatment with low molecular weight heparin (enoxaparin
40 mg daily) is a reasonable alternative if renal function is
normal (Class IIB, Level of Evidence C).
Nutrition
As is the case with all critically ill neurological patients,
enteral feeding should be started within 48 hours to avoid
protein catabolism and malnutrition. A small-bore nasoduo-
denal feeding tube may reduce the risk of aspiration events.
Surgical intervention for intracerebral hemorrhage
Craniotomy has been the most studied intervention for the
surgical management of ICH but the results have been dis-
couraging. Two earlier smaller trials showed that for patients
presenting with moderate alterations in the state of conscious-
ness, surgery reduced the risk of death without improving the
functional outcome [142] and that ultra-early evacuation might
improve the 3-month NIHSS [143]. Nevertheless, in a meta-
analysis of all prior trials of surgical intervention for
supratentorial ICH, no benefit was demonstrated [144].
The International Surgical Trial in Intracerebral Haemorrhage
(STICH) study, a landmark trial of over 1,000 ICH patients,
showed that emergent surgical hematoma evacuation via
craniotomy within 72 hours of onset fails to improve outcome
compared to a policy of initial medical management [145].
Although the STICH has rightfully dampened the enthusiasm
of neurosurgeons for performing surgery, it must be remem-
bered that the trial was based on the principle of clinical
equipoise and patients who the local investigator felt would
most likely benefit from emergency surgery were not enrolled
into the study. In a post hoc analysis of the STICH, the
subgroup of patients with superficial hematomas and no IVH
had better outcomes in the surgical arm [146]. This
observation provided support for the STICH-II, which is
currently enrolling patients [147]. In contrast to supratentorial
ICH, there is much better evidence that cerebellar hemor-
rhages exceeding 3 cm in diameter benefit from emergent
surgical evacuation as abrupt and dramatic deterioration to
coma can occur within the first 24 hours of onset in these
patients (Class I, Level of evidence B) [148]. For this reason,
it is generally unwise to defer surgery in these patients until
further clinical deterioration occurs.
As emergent craniotomy has been unable to improve
neurological outcome after ICH, the role of other surgical
techniques such as minimally invasive surgery have gained
importance over the past decade. The advantages of
minimally invasive surgery over conventional craniotomy
include reduced operative time, the possibility of performance
under local anesthesia, and reduced surgical trauma.
Endoscopic aspiration of supratentorial ICH was studied in a
small single-center randomized controlled trial (Class IIB,
Level of Evidence B) [149]. The study showed that this
technique provided a reduction of mortality rate at 6 months
in the surgical group but surgery was more effective in
superficial hematomas and in younger patients (<60 years).
Thrombolytic therapy and surgical removal of hematomas is
another technique that has been studied in a single center
randomized clinical trial (Class IIB, Level of Evidence B)
[143]. Patients in the surgical group had better outcome
scores than the medically treated group. Finally, a multi-
center randomized control trial examined the utility of
sterotactic urokinase infusion when administered within
72 hours to patients with GCS score ≥5 and hematomas
≥10 ml [150]; this provided significant reduction in hematoma
size and mortality rate at the expense of higher rates of re-
bleeding but no significant differences in outcomes measures
was seen.
Hemicraniectomy with duraplasty has been proposed as a
life-saving intervention for several neurological catastrophes,
such as malignant middle cerebral artery infarction and poor
grade subarachnoid hemorrhage. No randomized controlled
trial has been conducted in patients with ICH. In a recent
report of 12 consecutive patients with hypertensive ICH and
treated with hemicraniectomy, 11 (92%) survived at
discharge and 6 of them (54.5%) had a good functional
outcome (modified Rankin Score 0 to 3) [151]. These
preliminary data support the need for better controlled
studies addressing the role of this surgical technique in ICH
patients (Class IIB, Level of Evidence B).
Conclusions
Despite a long history of devastating outcomes and high
mortality, there is optimism that the management of ICH will
change in the future based on new insights into the acute
pathophysiology of this disease. A better understanding of
the dynamic process of hematoma growth, importance of
inflammation triggered by coagulation and products of blood
degradation, and the deleterious effects of fever and
hyperglycemia may provide feasible targets for future
interventions. A recent setback in the form of a negative
phase III trial evaluating ultra-early hemostatic therapy with
rFVIIa for acute ICH has led researchers to investigate CT
angiography as a method for identifying patients with contrast
extravasation and an increased risk of active bleeding. Other
promising approaches that deserve further study include
thrombolytic therapy for IVH [138], minimally invasive surgery
for clot lysis [152], and the development of novel anti-
inflammatory agents that target coagulation-induced peri-
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metalloproteinases, and vascular endothelial growth factor
[153]. These advances will hopefully lead to new optimism for
what has historically been one of the most devastating
illnesses in clinical medicine, and establish ICH as a medically
treatable condition worthy of aggressive ICU support.
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